Coronary Artery Disease Clinical Trials

A listing of 65 Coronary Artery Disease clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Coronary Artery Disease

1 - 12 of 65

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 65 active clinical trials seeking participants for Coronary Artery Disease research studies. The states with the highest number of trials for Coronary Artery Disease participants are Florida, California, New York and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Heart Failure Clinical Trial

Recruiting

You or someone you love may be eligible for a heart failure clinical study. Eligible participants will receive study-related assessments, care, and treatment at no cost. You may be reimbursed for travel while participating. See if you are eligible.

Conditions:

Heart Failure

Congestive Heart Failure

Chronic Heart Failure

Heart Failure

Congestive

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD

NCT06713239

Recruiting

PARAMOUNT is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary atherosclerotic plaque assessment by AI-enabled quantitative software improves: certainty for diagnosis of CAD, control of CAD risk factors and efficiency of ICA referral with appropriate PCI compared to the usual care strategy based on current AHA/ACC guidelines for care of symptom... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/30/2025

Locations: Cardiology Associates of Mobile, Mobile, Alabama +14 locations

Conditions: Coronary Artery Disease

Learn More ›

RADIQAL Study (Radiation Dose and Image Quality Trial)

NCT06944509

Recruiting

The Azurion R4.0 is developed by Philips Medical Systems Nederland B.V., a Philips Healthcare company. The Azurion is an interventional X-ray system which is used for live X-ray imaging during invasive cardiac procedures. The proposed Azurion R4.0 includes new x-ray image postprocessing (Xres5) compared to its predecessor, which was equipped with ClarityIQ image post-processing (Xres4). Azurion R4.0 is a cleared device for EU-MDR regulated countries, submission for FDA510K clearance in the US i... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: University of Colorado, Denver, Colorado +5 locations

Conditions: Coronary Artery Disease

Learn More ›

PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]

NCT05994014

Recruiting

Early detection of coronary atherosclerotic disease facilitates adequate prevention. The purpose of this study is to compare an assessment of coronary atherosclerotic disease burden by positron emission tomography / computed tomography (NaF-PET/CT) with those of conventional and ultra-high-resolution-CT (UHR-CT) in patients with suspected coronary artery disease. For this purpose, the investigators plan to include 33 patients with symptoms concerning for CAD who have been referred for cardiac CT... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/29/2025

Locations: Johns Hopkins Hospital, Baltimore, Maryland

Conditions: Coronary Artery Disease, Atherosclerosis, Coronary Atherosclerosis of Native Coronary Artery

Learn More ›

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine

NCT05850091

Recruiting

The goal of this double-blind randomized controlled trial is to determine how treatment with high intensity statin, low-dose colchicine, and their combination modulates progression and composition of coronary atherosclerosis in individuals with high polygenic risk for coronary artery disease.

Gender:

ALL

Ages:

Between 40 years and 75 years

Trial Updated:

07/28/2025

Locations: Massachusetts General Hospital, Boston, Massachusetts

Conditions: Coronary Artery Disease

Learn More ›

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health

NCT05819814

Recruiting

The goal of this randomized controlled trial is to assess the impact of disclosing a high polygenic risk result for coronary artery disease on change in cardiovascular health over one year.

Gender:

ALL

Ages:

Between 40 years and 75 years

Trial Updated:

07/28/2025

Locations: Massachusetts General Hospital, Boston, Massachusetts

Conditions: Coronary Artery Disease

Learn More ›

Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE)

NCT06181240

Recruiting

The FRACTURE Trial is a prospective, non-randomized, single-arm, multicenter, interventional study in US and international centers.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/25/2025

Locations: Scripps Health, La Jolla, California +33 locations

Scripps Health, La Jolla, California

Riverside Community Hospital, Riverside, California

Los Robles Hospital & Medical Center, Thousand Oaks, California

Medical Center of the Rockies, Loveland, Colorado

The Cardiac & Vascular Institute, Gainesville, Florida

HCA FL Memorial Hospital, Jacksonville, Florida

HCA Florida Largo Hospital, Largo, Florida

Northeast Georgia Medical Center, Gainesville, Georgia

Wellstar Research Institute, Hiram, Georgia

Brigham and Women's Hospital, Boston, Massachusetts

Massachusetts General Hospital, Boston, Massachusetts

Trinity Health Michigan Heart, Ypsilanti, Michigan

North Mississippi Medical Center, Tupelo, Mississippi

Montefiore Medical Center, Bronx, New York

The Icahn School of Medicine at Mt. Sinai, New York, New York

Nyph/Cuimc, New York, New York

Tristar Centennial Medical Center, Nashville, Tennessee

Methodist Healthcare Methodist Research Institute, San Antonio, Texas

Chippenham Johnson Willis Hospital, Richmond, Virginia

Onze-Lieve-Vrouwziekenhuis, afgekort OLV ziekenhuis, Aalst, Not set

Aarhus University Hospital, Aarhus, Not set

Segeberger Kliniken GmbH,, Bad Segeberg, Not set

SJG St. Paulus GmbH, St.-Johannes-Hospital Dortmund, Dortmund, Not set

Cellitinnen Krankenhaus St. Vinzenz, Köln, Not set

Klaipeda University Hospital, Klaipėda, Not set

Vilnius University Hospital Santaros Klinikos, Vilnius, Not set

Amsterdam University Medical Center, Amsterdam, Not set

Erasmus Medical Center, Rotterdam, Not set

Harefield Hospital, Harefield, Not set

Royal Free Hospital, London, Not set

St. Thomas' Hospital, London, Not set

King's College Hospital, London, Not set

St George's University of London, London, Not set

Royal Brompton Hospital, London, Not set

Conditions: Coronary Artery Disease, Coronary Artery Calcification

Learn More ›

Product Surveillance Registry

NCT01524276

Recruiting

The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.

Gender:

ALL

Ages:

All

Trial Updated:

07/24/2025

Locations: Not set, Birmingham, Alabama +381 locations

Not set, Birmingham, Alabama

Not set, Huntsville, Alabama

Not set, Chandler, Arizona

Not set, Phoenix, Arizona

Not set, Little Rock, Arkansas

Not set, Aliso Viejo, California

Not set, Chula Vista, California

Not set, Colton, California

Not set, La Jolla, California

Not set, Los Angeles, California

Not set, Napa, California

Not set, Redwood City, California

Not set, Salinas, California

Not set, San Diego, California

Not set, Stanford, California

Not set, Torrance, California

Not set, Ventura, California

Not set, Aurora, Colorado

Not set, Colorado Springs, Colorado

Not set, Lakewood, Colorado

Not set, Darien, Connecticut

Not set, Hartford, Connecticut

Not set, New Haven, Connecticut

Not set, Washington, District of Columbia

Not set, Bradenton, Florida

Not set, Clearwater, Florida

Not set, Davie, Florida

Not set, Jacksonville, Florida

Not set, Naples, Florida

Not set, Panama City, Florida

Not set, Safety Harbor, Florida

Not set, Sarasota, Florida

Not set, Weston, Florida

Not set, Gainesville, Georgia

Not set, Chicago, Illinois

Not set, Evansville, Indiana

Not set, Indianapolis, Indiana

Not set, Iowa City, Iowa

Not set, West Des Moines, Iowa

Not set, Kansas City, Kansas

Not set, Edgewood, Kentucky

Not set, Louisville, Kentucky

Not set, New Orleans, Louisiana

Not set, Hyattsville, Maryland

Not set, Salisbury, Maryland

Not set, Silver Spring, Maryland

Not set, Boston, Massachusetts

Not set, Holyoke, Massachusetts

Not set, Ann Arbor, Michigan

Not set, Bay City, Michigan

Not set, Lansing, Michigan

Not set, Rochester Hills, Michigan

Not set, Ypsilanti, Michigan

Not set, Coon Rapids, Minnesota

Not set, Minneapolis, Minnesota

Not set, Robbinsdale, Minnesota

Not set, Rochester, Minnesota

Not set, Saint Cloud, Minnesota

Not set, Jackson, Mississippi

Not set, Columbia, Missouri

Not set, Kansas City, Missouri

Not set, St. Louis, Missouri

Not set, Omaha, Nebraska

Not set, Lebanon, New Hampshire

Not set, Camden, New Jersey

Not set, Marlton, New Jersey

Not set, Morristown, New Jersey

Not set, Ocean Township, New Jersey

Not set, Teaneck, New Jersey

Not set, Albuquerque, New Mexico

Not set, Albany, New York

Not set, Bay Shore, New York

Not set, Huntington, New York

Not set, Manhasset, New York

Not set, Mount Kisco, New York

Not set, New Hyde Park, New York

Not set, New York, New York

Not set, Poughkeepsie, New York

Not set, Riverhead, New York

Not set, Roslyn, New York

Not set, Staten Island, New York

Not set, Stony Brook, New York

Not set, Utica, New York

Not set, Chapel Hill, North Carolina

Not set, Charleston, North Carolina

Not set, Durham, North Carolina

Not set, Pinehurst, North Carolina

Not set, Raleigh, North Carolina

Not set, Winston Salem, North Carolina

Not set, Cleveland, Ohio

Not set, Columbus, Ohio

Not set, Dayton, Ohio

Not set, Mount Orab, Ohio

Not set, Portland, Oregon

Not set, Allentown, Pennsylvania

Not set, Bethlehem, Pennsylvania

Not set, Danville, Pennsylvania

Not set, Erie, Pennsylvania

Not set, Lancaster, Pennsylvania

Not set, Mechanicsburg, Pennsylvania

Not set, Pittsburgh, Pennsylvania

Not set, Wilkes-Barre, Pennsylvania

Not set, Charleston, South Carolina

Not set, Columbia, South Carolina

Not set, Orangeburg, South Carolina

Not set, Spartanburg, South Carolina

Not set, Sioux Falls, South Dakota

Not set, Germantown, Tennessee

Not set, Memphis, Tennessee

Not set, Nashville, Tennessee

Not set, Austin, Texas

Not set, Dallas, Texas

Not set, Ft. Worth, Texas

Not set, Houston, Texas

Not set, Kyle, Texas

Not set, Plano, Texas

Not set, San Antonio, Texas

Not set, Tyler, Texas

Not set, Salt Lake City, Utah

Not set, Burlington, Vermont

Not set, Charlottesville, Virginia

Not set, Fairfax, Virginia

Not set, Fredericksburg, Virginia

Not set, Bremerton, Washington

Not set, Seattle, Washington

Not set, Spokane, Washington

Not set, Morgantown, West Virginia

Not set, Madison, Wisconsin

Not set, Milwaukee, Wisconsin

Not set, Buenos Aires, Not set

Not set, Westmead, New South Wales

Not set, Chermside, Not set

Not set, Murdoch, Not set

Not set, Southport, Not set

Not set, Innsbruck, Not set

Not set, Linz, Not set

Not set, Aalst, Not set

Not set, Brugge, Not set

Not set, Brussel, Not set

Not set, Edegem, Not set

Not set, Genk, Not set

Not set, Gent, Not set

Not set, Leuven, Not set

Not set, Liege, Not set

Not set, Roeselare, Not set

Not set, Sint-Niklaas, Not set

Not set, São Paulo, Not set

Not set, Calgary, Alberta

Not set, Kingston, Ontario

Not set, Montreal, Quebec

Not set, Quebec City, Not set

Not set, Quebec, Not set

Not set, Toronto, Not set

Not set, Chengdu, Sichuan

Not set, Beijing, Not set

Not set, Chengdu, Not set

Not set, Dalian, Not set

Not set, Guangzhou, Not set

Not set, Hangzhou, Not set

Not set, Harbin, Not set

Not set, Kunming, Not set

Not set, Nanchang, Not set

Not set, Shanghai, Not set

Not set, Suzhou, Not set

Not set, Medellin, Not set

Not set, Pereira, Not set

Not set, Rionegro, Not set

Not set, Praha, Not set

Not set, Hellerup, Not set

Not set, Hillerød, Not set

Not set, Kobenhavn, Not set

Not set, Odense, Not set

Not set, Helsinki, Not set

Not set, Tampere, Not set

Not set, Avignon, Not set

Not set, Bordeaux, Not set

Not set, Boulogne-Billancourt, Not set

Not set, Brest Cedex, Not set

Not set, Caen, Not set

Not set, Chambray, Not set

Not set, Clermont Ferrand, Not set

Not set, Créteil, Not set

Not set, Dijon, Not set

Not set, La Rochelle, Not set

Not set, La Tronche, Not set

Not set, Lille Cedex, Not set

Not set, Marseille Cedex 5, Not set

Not set, Montpellier Cedex 5, Not set

Not set, Nantes, Not set

Not set, Ollioules, Not set

Not set, Paris, Not set

Not set, Pessac, Not set

Not set, Pringy, Not set

Not set, Rennes, Not set

Not set, Saint-Priest-en-Jarez, Not set

Not set, Strasbourg, Not set

Not set, Toulouse Cedex 9, Not set

Not set, Villeurbanne, Not set

Not set, Aachen, Not set

Not set, Arnsberg, Not set

Not set, Bad Oeynhausen, Not set

Not set, Berlin, Not set

Not set, Bochum, Not set

Not set, Bremen, Not set

Not set, Düsseldorf, Not set

Not set, Freiburg, Not set

Not set, Hagen, Not set

Not set, Halle (Saale), Not set

Not set, Hamburg, Not set

Not set, Hannover, Not set

Not set, Heidelberg, Not set

Not set, Jena, Not set

Not set, Karlsruhe, Not set

Not set, Köln, Not set

Not set, Leipzig, Not set

Not set, Lübeck, Not set

Not set, Munster, Not set

Not set, München, Not set

Not set, Stuttgart, Not set

Not set, Tubingen, Not set

Not set, Ulm, Not set

Not set, Wiesbaden, Not set

Not set, Athens, Not set

Not set, Maroúsi, Not set

Not set, Thessaloníki, Not set

Not set, Hong Kong, Not set

Not set, Budapest, Not set

Not set, Hyderabad, Telangana

Not set, Bangalore, Not set

Not set, Bengaluru, Not set

Not set, Chennai, Not set

Not set, Gurugram, Not set

Not set, New Delhi, Not set

Not set, Galway, Not set

Not set, Ashkelon, Not set

Not set, Be'er Sheva, Not set

Not set, Jerusalem, Not set

Not set, Ramat Gan, Not set

Not set, Acquaviva Delle Fonti, Not set

Not set, Ancona, Not set

Not set, Bari, Not set

Not set, Bologna, Not set

Not set, Brescia, Not set

Not set, Caserta, Not set

Not set, Castrovillari, Not set

Not set, Cotignola, Not set

Not set, Lecce, Not set

Not set, Milano, Not set

Not set, Modena, Not set

Not set, Monza, Not set

Not set, Palermo, Not set

Not set, Pisa, Not set

Not set, Roma, Not set

Not set, Rome, Not set

Not set, Taranto, Not set

Not set, Udine, Not set

Not set, Sakai, Osaka

Not set, Ageo, Saitama

Not set, Hidaka, Saitama

Not set, Koshigaya, Saitama

Not set, Tokyo, Tachikawa

Not set, Bunkyō-Ku, Tokyo

Not set, Minato-Ku, Tokyo

Not set, Yonago, Tottori

Not set, Chiba, Not set

Not set, Fukui, Not set

Not set, Fukuoka, Not set

Not set, Gifu, Not set

Not set, Hirosaki, Not set

Not set, Hiroshima City, Not set

Not set, Hiroshima, Not set

Not set, Kagoshima, Not set

Not set, Kamakura, Not set

Not set, Kawasaki, Not set

Not set, Kitakyushu, Not set

Not set, Kofu, Not set

Not set, Kumamoto, Not set

Not set, Kyoto, Not set

Not set, Mitaka, Not set

Not set, Nagoya, Not set

Not set, Niigata, Not set

Not set, Okayama, Not set

Not set, Sapporo, Not set

Not set, Shinagawa-Ku, Not set

Not set, Shizuoka, Not set

Not set, Suita, Not set

Not set, Tokyo, Not set

Not set, Toyoake, Not set

Not set, Urasoe, Not set

Not set, Yokohama, Not set

Not set, Ōsaka-sayama, Not set

Not set, Yangsan, Gyeongsangnam-do

Not set, Busan, Not set

Not set, Changwon, Not set

Not set, Cheongju-si, Not set

Not set, Daegu, Not set

Not set, Daejeon, Not set

Not set, Gangneung, Not set

Not set, Gwangju, Not set

Not set, Gyeonggi-do, Not set

Not set, Incheon, Not set

Not set, Jeonju, Not set

Not set, Seongnam-si, Not set

Not set, Seoul, Not set

Not set, Suwon-si, Not set

Not set, Kuwait, Not set

Not set, Kuala Lumpur, Not set

Not set, Ciudad de mexico, Not set

Not set, Den Haag, Not set

Not set, Doetinchem, Not set

Not set, Eindhoven, Not set

Not set, Enschede, Not set

Not set, Groningen, Not set

Not set, Heerlen, Not set

Not set, Hengelo, Not set

Not set, Leiden, Not set

Not set, Maastricht, Not set

Not set, Nieuwegein, Not set

Not set, Rotterdam, Not set

Not set, Christchurch, Not set

Not set, Bergen, Not set

Not set, Lorenskog, Not set

Not set, Trondheim, Not set

Not set, Panama, Not set

Not set, Poznań, Not set

Not set, Warszawa, Not set

Not set, Zabrze, Not set

Not set, Carnaxide, Not set

Not set, Creixomil, Not set

Not set, Lisboa, Not set

Not set, Porto, Not set

Not set, Santarém, Not set

Not set, Aibonito, Not set

Not set, Rio Piedras, Not set

Not set, Jeddah, Not set

Not set, Riyadh, Not set

Not set, Belgrade, Not set

Not set, Bratislava, Not set

Not set, A Coruña, Not set

Not set, Barcelona, Not set

Not set, Córdoba, Not set

Not set, Elche, Not set

Not set, Girona, Not set

Not set, Granada, Not set

Not set, L'Hospitalet De Llobregat, Not set

Not set, Madrid, Not set

Not set, Málaga, Not set

Not set, Palma De Mallorca, Not set

Not set, Salamanca, Not set

Not set, Santa Cruz De Tenerife, Not set

Not set, Santiago De Compostela, Not set

Not set, Toledo, Not set

Not set, Valencia, Not set

Not set, Valladolid, Not set

Not set, Vitoria-Gasteiz, Not set

Not set, Skövde, Not set

Not set, Basel, Not set

Not set, Bern, Not set

Not set, Fribourg, Not set

Not set, Geneve, Not set

Not set, Lausanne, Not set

Not set, Lugano, Not set

Not set, Morges, Not set

Not set, Zürich, Not set

Not set, Taichung, Not set

Not set, Barnstaple, Not set

Not set, Birmingham, Not set

Not set, Blackpool, Not set

Not set, Bristol, Not set

Not set, Chelmsford, Not set

Not set, Glasgow, Not set

Not set, Harrow, Not set

Not set, Leeds, Not set

Not set, Leicester, Not set

Not set, Liverpool, Not set

Not set, London, Not set

Not set, Manchester, Not set

Not set, Middlesbrough, Not set

Not set, Newcastle Upon Tyne, Not set

Not set, Northampton, Not set

Not set, Sheffield, Not set

Not set, Southampton, Not set

Conditions: Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder

Learn More ›

Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions (BIOFLOW-48) Study

NCT06779630

Recruiting

The purpose of the study is to assess the safety and efficacy of the Orsiro® Mission 48- mm Sirolimus-Eluting Coronary Stent System in the treatment of subjects with atherosclerotic lesion(s) \>36 mm and ≤ 44 mm in length (by visual estimate) in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4.0 mm. Patients enrolled in the United States will be followed for 2 years post index procedure with follow-up visits at 1, 6, 12 months and 2 years post index procedure. Patie... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/22/2025

Locations: Charleston Area Medical Center, Charleston, West Virginia

Conditions: Coronary Artery Disease

Learn More ›

Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

NCT04634240

Recruiting

Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise regarding the management of concomitant CAD in patients undergoing TAVR. Some centers perform routine revascularization with percutaneous coronary intervention (PCI) (either before or after TAVR), while others follow an alternative strategy of medical management. The potential benefits and optimal timing of PCI in these patients are unknown. As TAVR expands to lower risk patients, and potentially becomes the preferred therapy for the majority of patients with severe aortic stenosis, the optimal management of concomitant coronary artery disease will be of increasing importance. The COMPLETE TAVR study will determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the composite outcome of Cardiovascular Death, new Myocardial Infarction, Ischemia-driven Revascularization or Hospitalization for Unstable Angina or Heart Failure. The study will be a randomized, multicenter, open-label trial with blinded adjudication of outcomes. Patients will be screened and consented for elective transfemoral TAVR and randomized within 96 hours of successful balloon expandable TAVR. Complete Revascularization: Staged PCI using third generation drug eluting stents to treat all suitable coronary artery lesions in vessels that are at least 2.5 mm in diameter and that are amenable to treatment with PCI and have a ≥70% visual angiographic diameter stenosis. Staged PCI can occur any time from 1 to 45 days post successful transfemoral TAVR. Vs. Medical Therapy Alone: No further revascularization of coronary artery lesions. All patients, regardless of randomized treatment allocation, will receive guideline-directed medical therapy consisting of risk factor modification and use of evidence-based therapies. The COMPLETE TAVR study will help address the current lack of evidence in this area. It will likely impact both the global delivery of health care and the management and clinical outcomes of all patients undergoing TAVR with concomitant CAD. Read Less

Gender:

ALL

Ages:

All

Trial Updated:

07/22/2025

Locations: Huntsville Heart Center, Huntsville, Alabama +71 locations

Huntsville Heart Center, Huntsville, Alabama

Arizona Cardiovascular Research, Phoenix, Arizona

Veteran Affairs Palo Alto Health Care System, Palo Alto, California

Loma Linda University, Redlands, California

Santa Barbara Cottage Hospital, Santa Barbara, California

Torrance Memorial Medical Center, Torrance, California

JFK Medical Center, Atlantis, Florida

Baptist Health Jacksonville, Jacksonville, Florida

Miami Cardiac and Vascular/Baptist Hospital, Miami, Florida

Piedmont, Atlanta, Georgia

Northeast Georgia Health System, Gainesville, Georgia

St. Alphonsus Regional Medical Center, Boise, Idaho

Ascension Alexian Brothers, Chicago, Illinois

Midwest Cardiovascular Research and Education Foundation, Elkhart, Indiana

Parkview Research Center, Fort Wayne, Indiana

University of Kansas Medical Center, Kansas City, Kansas

Midwest Heart and Vascular, Overland Park, Kansas

Cardiovascular Research Institute of Kansas, Wichita, Kansas

Tufts Medical, Boston, Massachusetts

Massachusetts General Hospital, Boston, Massachusetts

Sparrow Clinical Research Institute, Lansing, Michigan

William Beaumont Hospital, Royal Oak, Michigan

Ascension St. Mary's, Saginaw, Michigan

St. Joseph Mercy Health System, Ypsilanti, Michigan

University of Minnesota Medical Center, Minneapolis, Minnesota

CentraCare Heart and Vascular Center, Saint Cloud, Minnesota

Boone Hospital, Columbia, Missouri

St. Louis University, Saint Louis, Missouri

Missouri Baptist, Saint Louis, Missouri

Bryan Heart, Lincoln, Nebraska

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Our Lady of Lourdes, Camden, New Jersey

Valley Hospital, Ridgewood, New Jersey

Montefiore Medical Center, Bronx, New York

University at Buffalo, Buffalo, New York

NYU Langone Hospital - Long Island, Mineola, New York

Mount Sinai, New York, New York

Columbia University Medical Center, New York, New York

St. Joseph's Hospital, Syracuse, New York

Novant Health Heart and Vascular Institute, Charlotte, North Carolina

Summa Health System, Akron, Ohio

Mount Carmel, Columbus, Ohio

Oklahoma Heart, Oklahoma City, Oklahoma

Kaiser Permanente Northwest, Clackamas, Oregon

Rhode Island Hospital, Providence, Rhode Island

Methodist Le Bonheur Healthcare, Germantown, Tennessee

Ballad Health CVA Heart Institute, Kingsport, Tennessee

Parkwest Medical Center, Knoxville, Tennessee

Cardiovascular Surgery Clinic/Baptist Memorial, Memphis, Tennessee

HCA Houston Healthcare Medical Center, Houston, Texas

Baylor Scott & White Plano, Plano, Texas

Baylor Scott & White Round Rock, Round Rock, Texas

University of Vermont Medical Center, Burlington, Vermont

Bellin Health System, Green Bay, Wisconsin

Ascension Columbia St. Mary's, Milwaukee, Wisconsin

University of Alberta, Mazankowski Heart Institute, Edmonton, Alberta

Royal Columbian Hospital, New Westminster, British Columbia

Vancouver General Hospital, Vancouver, British Columbia

Centre for Cardiovascular Innovation-Centre d'Innovation Cardiovasculaire (CCI-CIC), Vancouver, British Columbia

St. Paul's Hospital, Vancouver, British Columbia

Saint Boniface, Winnipeg, Manitoba

New Brunswick Heart, Saint John, New Brunswick

Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia

Hamilton Health Sciences, Hamilton, Ontario

Ottawa Heart, Ottawa, Ontario

Sunnybrook Hospital, Toronto, Ontario

St. Michael's Hospital, Toronto, Ontario

Montréal Heart, Montréal, Quebec

Centre Hospitalier de l'Université de Montréal, Montréal, Quebec

Sacré-Coeur, Montréal, Quebec

CIUSSS de l'Estrie-CHUS, Sherbrooke, Quebec

Prairie Vascular, Regina, Saskatchewan

Conditions: Aortic Stenosis, Coronary Artery Disease, Coronary Stenosis

Learn More ›

Myocardial Perfusion Imaging Galmydar Rest/Stress

NCT05625490

Recruiting

A single center, phase 0/1 clinical imaging study designed to assess the role of \[68Ga\]Galmydar PET/CT imaging in human subjects.

Gender:

ALL

Ages:

Between 18 years and 99 years

Trial Updated:

07/16/2025

Locations: Washington University School of Medicine, Saint Louis, Missouri

Conditions: Coronary Artery Disease

Learn More ›

Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors

NCT05611307

Recruiting

Late subclinical cardiovascular disease in testicular cancer survivors exposed to cisplatin-based chemotherapy and bone marrow transplant

Gender:

MALE

Ages:

Between 18 years and 99 years

Trial Updated:

07/16/2025

Locations: Indiana University, Indianapolis, Indiana

Conditions: Testicular Cancer, Survivorship, ASCVD, Coronary Artery Disease, Lipid Disorder, Hypogonadism, Male, Cisplatin Adverse Reaction, Bone Marrow Transplant Complications

Learn More ›

CTSN Embolic Protection Trial

NCT06027788

Recruiting

This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.

Gender:

ALL

Ages:

60 years and above

Trial Updated:

07/15/2025

Locations: CHI St. Vincent Heart Institute, North Little Rock, Arkansas +27 locations

CHI St. Vincent Heart Institute, North Little Rock, Arkansas

Keck Hospital of the University of Southern California, Los Angeles, California

Emory University, Atlanta, Georgia

Indiana University, Bloomington, Indiana

Indiana Ohio Heart, Fort Wayne, Indiana

Ochsner Clinic, New Orleans, Louisiana

Maine Medical Center, Portland, Maine

Johns Hopkins Medicine, Baltimore, Maryland

University of Maryland, College Park, Maryland

Massachusetts General Hospital, Boston, Massachusetts

University of Michigan, Ann Arbor, Michigan

Mayo Clinic, Rochester, Minnesota

Saint Luke's Hospital of Kansas City, Kansas City, Missouri

Montefiore Medical Center, Bronx, New York

Columbia University Medical Center, New York, New York

New York Presbyterian-Cornell Medical Center, New York, New York

NYU Langone Hospital Brooklyn, New York, New York

Northwell Health, New York, New York

Duke University, Durham, North Carolina

University Hospitals, Cleveland, Ohio

Cleveland Clinic, Cleveland, Ohio

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

University of Virginia, Charlottesville, Virginia

West Virginia University, Morgantown, West Virginia

London Health Sciences Centre, London, Ontario

University of Ottawa Heart Institute, Ottawa, Ontario

Montreal Heart Institute, Montréal, Quebec

Hôpital Laval, Quebec City, Quebec

Conditions: Delirium, Ischemic Stroke, Acute Kidney Injury, Heart Valve Disease, Coronary Artery Disease

Learn More ›

1 - 12 of 65